Diabetic Med:在诊断为前驱糖尿病后进行饮食改变?

2018-12-28 MedSci MedSci原创

近日,国际杂志 《Diabetic Med》上在线发表一项关于在在诊断为前驱糖尿病后进行饮食改变:对障碍和促进进行定性探索的研究。探讨最近被诊断患有前驱糖尿病和超重或肥胖的人在六个月初级保健护士提供的饮食干预试点后进行饮食改变的经历。 研究人员对20名参与者进行了半结构式访谈,目的是为了确保种族,性别和血糖结果在分组中的比例。对访谈数据进行了专题分析。 参与者描述了在诊断为前驱糖尿病

近日,国际杂志 《Diabetic Med》上在线发表一项关于在在诊断为前驱糖尿病后进行饮食改变:对障碍和促进进行定性探索的研究。探讨最近被诊断患有前驱糖尿病和超重或肥胖的人在六个月初级保健护士提供的饮食干预试点后进行饮食改变的经历。

研究人员对20名参与者进行了半结构式访谈,目的是为了确保种族,性别和血糖结果在分组中的比例。对访谈数据进行了专题分析。

参与者描述了在诊断为前驱糖尿病诊断时感到震惊。出现了三个核心主题,每个主题包含子主题:(i)支持性因素-决心不发展糖尿病,明确信息和可管理的策略,以及支持性关系; ii)障碍 - 缺乏家庭支持,经济限制,围绕食物的社会期望和慢性健康问题;(iii)克服挑战-种植和分享食物,使用冷冻蔬菜和规划。土著毛利人参与者对提供和分享食物的文化期望所带来的挑战更为明显。

研究表明,前驱糖尿病的诊断为医疗保健专业人员提供了一个窗口,可以与那些被诊断出来的人及其家人一起进行健康的饮食改变。当将个人的生活环境考虑到内,饮食指导可能是最有效的。明确的信息和支持性关系科促进生活方式的改变非常重要。

原始出处:

S. AbelL. C. WhiteheadK. J. Coppellet al. Making dietary changes following a diagnosis of prediabetes: a qualitative exploration of barriers and facilitators

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1970689, encodeId=2a2919e068922, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Fri Apr 26 10:55:00 CST 2019, time=2019-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638941, encodeId=22c21638941aa, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Sep 28 23:55:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760972, encodeId=f5af1e60972cd, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Mar 05 21:55:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609423, encodeId=0333160942335, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Dec 30 00:55:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042167, encodeId=3286104216e74, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Dec 28 12:55:00 CST 2018, time=2018-12-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1970689, encodeId=2a2919e068922, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Fri Apr 26 10:55:00 CST 2019, time=2019-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638941, encodeId=22c21638941aa, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Sep 28 23:55:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760972, encodeId=f5af1e60972cd, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Mar 05 21:55:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609423, encodeId=0333160942335, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Dec 30 00:55:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042167, encodeId=3286104216e74, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Dec 28 12:55:00 CST 2018, time=2018-12-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1970689, encodeId=2a2919e068922, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Fri Apr 26 10:55:00 CST 2019, time=2019-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638941, encodeId=22c21638941aa, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Sep 28 23:55:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760972, encodeId=f5af1e60972cd, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Mar 05 21:55:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609423, encodeId=0333160942335, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Dec 30 00:55:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042167, encodeId=3286104216e74, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Dec 28 12:55:00 CST 2018, time=2018-12-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1970689, encodeId=2a2919e068922, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Fri Apr 26 10:55:00 CST 2019, time=2019-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638941, encodeId=22c21638941aa, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Sep 28 23:55:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760972, encodeId=f5af1e60972cd, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Mar 05 21:55:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609423, encodeId=0333160942335, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Dec 30 00:55:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042167, encodeId=3286104216e74, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Dec 28 12:55:00 CST 2018, time=2018-12-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1970689, encodeId=2a2919e068922, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Fri Apr 26 10:55:00 CST 2019, time=2019-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638941, encodeId=22c21638941aa, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Sep 28 23:55:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760972, encodeId=f5af1e60972cd, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Mar 05 21:55:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609423, encodeId=0333160942335, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Dec 30 00:55:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042167, encodeId=3286104216e74, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Dec 28 12:55:00 CST 2018, time=2018-12-28, status=1, ipAttribution=)]
    2018-12-28 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

Diabetic Med:前驱糖尿病和糖尿病都是感染性心内膜炎不良后果的危险因素?

糖尿病是感染性心内膜炎的危险因素。然而,很少有研究关注前驱糖尿病在感染性心内膜炎中的预后价值。该分析旨在探讨前驱糖尿病与感染性心内膜炎患者预后之间的关系。近日,国际杂志 《Diabetic Med》上在线发表一项关于前驱糖尿病和糖尿病都是感染性心内膜炎不良后果的危险因素的研究。 糖尿病和前驱糖尿病定义基于美国糖尿病协会2014年标准。2009年1月至2015年7月期间共有866名被连续诊断

JAMA Intern Med:超过一半的成年人是前驱糖尿病高危人群

近期有研究表明:美国大多数≥40岁成年人,是前驱糖尿病高危人群。 来自塔夫茨医疗中心的Saeid Shahraz博士说:风险评估工具发现,≥40岁成年人中有60%、≥60岁人群中有80%,属于前驱糖尿病高危人群。 他们写道:糖尿病预防计划和其他的研究发现,糖耐量异常者(基于75g口服葡萄糖耐量试验),通过强化监督的生活方式干预,包括饮食和运动,以及二甲双胍治疗,可以降低2型糖尿病的风险

EASD 2016:利拉鲁肽可有效延缓2型糖尿病进展

第52届欧洲糖尿病学会年会(EASD 2016)称:对于前驱糖尿病成人患者,在饮食和运动的基础上,利拉鲁肽作为辅助药物,可有效延缓2型糖尿病的进展,并且能降低体重和空腹血糖。前驱糖尿病是指,在患有高血糖症和低血糖症的患者中,存在葡萄糖代谢障碍,但其并未达到标准的2型糖尿病诊断标准。丹麦Hvidovre医院的Sten Madsbad博士对2254例前驱糖尿病(平均年龄47.5岁;女性占76%)的超重

Exp Clin Endocr Diabe:警惕:前驱糖尿病人数已经超过糖尿病人数

近日,来自德国糖尿病研究中心发布了他们的研究数据,结果指出近四分之一的住院患者患有糖尿病,比例为22%,还有24%的住院患者有前驱糖尿病,进一步的研究结果证明,糖尿病患者住院时间更长,并发症的风险也更高。

IJIR:各种类型前驱糖尿病男性患者的性功能和抑郁症状分析

到目前为止,还没有研究针对不同类型的前驱糖尿病男性患者的性功能情况和抑郁症状进行比较。最近,有研究人员对上述研究空白进行了探索。他们的研究包括了4组年龄和体重匹配的男性(25-50岁):包括单独的空腹血糖异常(IFG)(n=16),单独的葡萄糖耐量异常(n=17),IFG和葡萄糖耐量异常同时包含(n=16)以及具有正常葡萄糖耐量(n=18)。所有研究中的男性均完成了评估男性性功能(IIEF-15)

Diabetologia:前驱糖尿病个体的异常肠道微生物群

近日,国际杂志 《Diabetologia》上在线发表一项关于前驱糖尿病个体的异常肠道微生物群的研究。 2型糖尿病患者会表现出肠道微生物异常。然而,最近的研究表明,二甲双胍有改变肠道微生物群的组成和功能的潜力,从而干扰与糖尿病有关的微生物标记。研究人员测试了特定的肠道微生物群特征是否与前驱糖尿病(定义为空腹血糖6.1-7.0mmol/l或HbA 1c 42-48mmol/mol [6.0-6